FindTrial
Sign In

PRI-724

DRUG6 trials

Sponsors

Prism Pharma Co., Ltd., Komagome Hospital, Kiminori Kimura, MD

Conditions

Acute Myeloid LeukemiaAdvanced Pancreatic CancerAdvanced Solid TumorsChronic Myeloid LeukemiaHepatitis BHepatitis CHepatitis C Virus-infected CirrhosisLiver Cirrhoses

Phase 1

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
TerminatedNCT01302405
Prism Pharma Co., Ltd.Advanced Solid Tumors
Start: 2011-02-28End: 2015-06-30Updated: 2017-08-17
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
CompletedNCT01606579
Prism Pharma Co., Ltd.Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Start: 2012-07-31End: 2016-12-30Updated: 2017-08-17
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
CompletedNCT01764477
Prism Pharma Co., Ltd.Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
Start: 2013-04-30End: 2015-10-31Updated: 2017-08-17
An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis
CompletedNCT02195440
Komagome HospitalHepatitis C Virus-infected Cirrhosis
Start: 2014-08-31End: 2017-03-31Updated: 2022-07-07
Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
CompletedNCT03620474
Kiminori Kimura, MDHepatitis B, Hepatitis C, Liver Cirrhoses
Start: 2018-07-24End: 2022-02-28Updated: 2024-10-10

Unknown Phase

A Follow-up Evaluation Study of PRI-724-1101
CompletedNCT02828254
Komagome HospitalHepatitis C Virus-infected Cirrhosis
Start: 2014-12-18End: 2018-01-31Updated: 2022-07-07

Related Papers

Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
2022-05-2037 citations
Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.
2017-08-1988 citations
Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Journal of Clinical Oncology2016-05-2068 citations
A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Journal of Clinical Oncology2015-05-2043 citations
Combination of Tyrosine Kinase Inhibitor with β-Catenin/CBP Modulator C82 Reverses TKI Resistance, Eradicates Quiescent CML Stem/Progenitors Cells, and Overcomes MSC-Associated Microenvironmental Protection
Blood2014-12-061 citations